Transaera, Inc. | $10,500,000 | (Nov 5, 2024)
Algebrik AI | $4,000,000 | (Nov 5, 2024)
Quanscient | $5,667,883 | (Nov 5, 2024)
March Biosciences
United States
- Houston, TX
- 10/11/2023
- Unknown
- $4,800,000
March Biosciences, Inc is a clinical-stage cell therapy company with a mission to transform patient care in the most challenging hematological malignancies. March Bio's lead asset is at the end of Phase I trials for T-cell malignancies, diseases with a dismal prognosis that is currently unaddressed by CAR-T and targeted therapy technologies. The company's pipeline is designed to expand on these early successes to more broadly impact other high-challenge cancers.
- Industry Biotechnology
- Website https://march.bio/
- LinkedIn https://www.linkedin.com/company/march-biosciences/about/
Related People
Sarah HeinCo Founder
United States -
Houston, Texas
Sarah is the founding CEO of March Biosciences, a clinical-stage cell-therapy company targeting challenging hematological malignancies. Prior to cofounding March Bio, she was the founding Entrepreneur in Residence for the Texas Medical Center Innovation Accelerator for Cancer Therapeutics (TMCi ACT). Formerly, she was a cofounder and the Vice President of Operations at Courier Therapeutics, a cancer immunotherapy startup acquired by Valo Health. She was also Director of Research at Resonant Therapeutics, an antibody therapeutics platform technology company. She began at Mercury Fund as a Venture Fellow directly after graduating with her PhD in Molecular Biology from Baylor College of Medicine.
Miros | $6,535,520 | (Nov 5, 2024)
Cintoo | $40,246,701 | (Nov 5, 2024)
Further | $4,100,000 | (Nov 5, 2024)
Plato | $6,500,000 | (Nov 5, 2024)
cloudsquid | $1,000,000 | (Nov 5, 2024)
Advex AI | $3,500,000 | (Nov 5, 2024)
Birl | $647,878 | (Nov 5, 2024)
Inquis Medical, Inc. | $40,000,000 | (Nov 5, 2024)
CrossBridge Bio | $10,000,000 | (Nov 5, 2024)